Neuroendocrine carcinomas (NECs) are uncommon and aggressive cancers with limited treatment options after the failure of platinum-based therapies. A recently concluded phase II trial investigated
The University of Pennsylvania is now enrolling patients in the new phase 1/2 multi-center clinical trial for CAR T cell therapy. The trial includes patients
NETRF is pleased to announce that Daniel Halperin, MD, one of our distinguished Board of Scientific Advisors members, has been appointed Vice Chair of Clinical
NETRF congratulates Dr. Michael Roehrl on his research progress and recent publication. NETRF’s recent Investigator Award to Michael Roehrl, MD, PhD, MBA, Chief of Pathology at…
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field of neuroendocrine tumor (NET) treatment. On August 6, 2024, Exelixis
Welcome to the latest research highlights from the Neuroendocrine Tumor Research Foundation (NETRF). In this blog post, we dive into two new research studies funded
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to funding groundbreaking research in neuroendocrine cancer, which includes neuroendocrine tumors (NETs) and neuroendocrine carcinomas
We did it! Thanks to our incredible NETRF community and the generous match from our board member Steve Kaufer, we raised over $115,000 for neuroendocrine
